Shots:
- Vara has received CE Class IIb marking under the EU MDR for its tomosynthesis (3D mammography) AI solution, expanding its offerings for breast cancer screening programs across the EU
- Vara is validated for national-scale breast cancer screening, with its scale demonstrated through PRAIM, a large prospective screening study published in Nature Medicine in 2025, supporting the use of AI to improve screening efficiency & quality
- Approval follows recent milestones, incl. CE marking for its independent second-reader solution & the launch of its three-prior AI model, with further announcements expected in the future, incl. Vara’s breast cancer risk prediction
Ref: Globenewswire | Image: Vara | Press Release
Related News: SpinaFX Receives the US FDA IDE Approval to Initiate Trial for Triojection Therapy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
